BrainsWay to Present Expanded Post-Marketing Clinical Research for Major Depressive Disorder at Clinical TMS Society

Additional presentations will highlight the utility of Deep TMS™ in Smoking Addiction and OCD

BURLINGTON, Mass. and JERUSALEM, May 04, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the Company will be presenting real world results for Deep TMS™ in the treatment of major depressive disorder at the upcoming Clinical TMS Society Annual Meeting in Chicago.

The Annual Meeting of the Clinical TMS Society provides a forum to connect with TMS providers and researchers from around the world. During the meeting, the Company will have seven poster presentations highlighting the potential of Deep TMS treatment for mental health disorders. For the depression post-marketing results, an analysis of data from 1,750 patients was conducted. In addition, practicing Deep TMS providers will be presenting original research on the technology from their practices.

“We are excited to be presenting these new data in this forum,” said Dr. Aron Tendler, BrainsWay’s Chief Medical Officer. “With three unique coils for three different indications, this expanding body of evidence helps providers better understand how to effectively utilize Deep TMS H-Coils to treat patients with these complex, resistant, and highly comorbid conditions. Our company’s goal is to increase the efficacy of noninvasive neurostimulation through technological improvements and research. We are also presenting data on a personalized medicine approach for patients seeking relief from their treatment-resistant depression.”

The Company will also be participating in other psychiatric conferences over the course of May and June including the American Psychiatric Association’s Annual Meeting in New Orleans, LA, European Brain Stimulation in Zagreb, Croatia, The Royal Australian & New Zealand Congress of Psychiatrists in Sydney, and Psych Congress Elevate in Las Vegas, NV.

About BrainsWay
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Burlington, MA and Jerusalem, Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.

Forward-Looking Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company’s anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company’s intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements.

Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company’s filings with the U.S. Securities and Exchange Commission.

Contacts:
Scott Areglado
SVP and Chief Financial Officer
617-771-2287
SAreglado@brainsway.com

Investors:
Bob Yedid
LifeSci Advisors
646-597-6989
Bob@LifeSciAdvisors.com

Media Contact:
Will Johnson
(201) 465-8019
BrainsWay@AntennaGroup.com